Sulfonylurea antidiabetics are associated with lower risk of out‐of‐hospital cardiac arrest: Real‐world data from a population‐based study

Out‐of‐hospital cardiac arrest (OHCA) mostly results from ventricular tachycardia/ventricular fibrillation (VT/VF), often triggered by acute myocardial infarction (AMI). Sulfonylurea (SU) antidiabetics can block myocardial ATP‐regulated K+ channels (KATP channels), activated during AMI, thereby modulating action potential duration (APD). We studied whether SU drugs impact on OHCA risk, and whether these effects are related to APD changes.

[1]  Christopher Southan,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels , 2019, British journal of pharmacology.

[2]  B. Zinman,et al.  Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. , 2019, JAMA.

[3]  H. Tan,et al.  Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries , 2019, European heart journal. Cardiovascular pharmacotherapy.

[4]  H. Tan,et al.  Socio-economic differences in incidence, bystander cardiopulmonary resuscitation and survival from out-of-hospital cardiac arrest: A systematic review. , 2019, Resuscitation.

[5]  Charles E. Leonard,et al.  Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia , 2018, Diabetes Care.

[6]  Charles E. Leonard,et al.  Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence , 2017, Trends in Endocrinology & Metabolism.

[7]  J. Garber,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  C. Brensinger,et al.  Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics , 2016, Clinical pharmacology and therapeutics.

[9]  H. Tan,et al.  Reduced pre-hospital and in-hospital survival rates after out-of-hospital cardiac arrest of patients with type-2 diabetes mellitus: an observational prospective community-based study. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  Patrick H. Pun.  The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. , 2014, Advances in chronic kidney disease.

[11]  H. Tan,et al.  Genetic, clinical and pharmacological determinants of out-of-hospital cardiac arrest: rationale and outline of the AmsteRdam Resuscitation Studies (ARREST) registry , 2014, Open Heart.

[12]  Donald M Bers,et al.  Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays , 2013, Circulation.

[13]  R. Herings,et al.  Pharmacy-Based Medical Record Linkage Systems , 2012 .

[14]  A. Vaag,et al.  Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. , 2011, European heart journal.

[15]  T. Rea,et al.  Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community , 2010, Reviews in Endocrine and Metabolic Disorders.

[16]  M. Khalangot,et al.  Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. , 2009, Diabetes research and clinical practice.

[17]  H. Huikuri,et al.  Sudden death due to cardiac arrhythmias. , 2001, The New England journal of medicine.

[18]  F. Ashcroft,et al.  Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells , 2001, Diabetologia.

[19]  F. Ashcroft,et al.  Glimepiride block of cloned β‐cell, cardiac and smooth muscle KATP channels , 2001 .

[20]  M. Hobbs,et al.  Arrhythmias and Mortality After Myocardial Infarction in Diabetic Patients: Relationship to diabetes treatment , 1998, Diabetes Care.

[21]  R. Barrett-Jolley,et al.  Characterization of KATP channels in intact mammalian skeletal muscle fibres , 1998 .

[22]  M. Arita,et al.  Pharmacological evidence for the persistent activation of ATP-sensitive K+ channels in early phase of reperfusion and its protective role against myocardial stunning. , 1995, Circulation.

[23]  ToshiakiSato,et al.  Pharmacological Evidence for the Persistent Activation of ATP-Sensitive K+ Channels in Early Phase of Reperfusion and Its Protective Role Against Myocardial Stunning , 1995 .

[24]  C. Fiorentini,et al.  Effects of glibenclamide on ventricular fibrillation in non‐insulin-dependent diabetics with acute myocardial infarction , 1994, Coronary artery disease.

[25]  H. Tan,et al.  Ischaemic preconditioning delays ischaemia induced cellular electrical uncoupling in rabbit myocardium by activation of ATP sensitive potassium channels. , 1993, Cardiovascular research.

[26]  M. Varricchio,et al.  Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. , 1991, The American journal of cardiology.

[27]  G. Grover,et al.  Pharmacologic Profile of Cromakalim in the Treatment of Myocardial Ischemia in Isolated Rat Hearts and Anesthetized Dogs , 1990, Journal of cardiovascular pharmacology.

[28]  M. Sanguinetti,et al.  Influence of ATP-sensitive potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts. , 1989, Journal of molecular and cellular cardiology.

[29]  M. A. O. Ignacio,et al.  How to cite this article , 2016 .

[30]  E. Falk,et al.  Mechanisms of Plaque Formation and Rupture , 2014 .

[31]  C. Bailey,et al.  Oral Antidiabetic Agents , 2012, Drugs.

[32]  C. Bailey,et al.  Oral antidiabetic agents: current role in type 2 diabetes mellitus. , 2005, Drugs.

[33]  A. Wilde,et al.  Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. , 1994, Cardiovascular research.